...Mamoru Nukatsuka; Akio Fujioka; Hideki Nagase; Gotaro Tanaka; Hiroaki Hayashi Introduction: Trifluridine/tipiracil hydrochloride (FTD/TPI, Lonsurf ® ) is an oral antineoplastic agent that has been approved as late-stage chemotherapy for colorectal cancer. Its major mechanism of action...

...Xianting Li; Xiaojiao Chen; Chendong Fu; Ming Xie; Shurui Ouyang Background: Oxaliplatin-based chemotherapy resistance is a major cause of recurrence in patients with colorectal cancer (CRC). Increasing evidence indicates that lncRNA BCAR4 is involved in the occurrence and development of various...

...Cunliang Zhu; Zhaobi Fang; Lei Peng; Fan Gao; Wei Peng; Fengqian Song Background: Irinotecan (IRI) is a common chemotherapeutic drug for colorectal cancer; however, the mechanism underlying its immunomodulatory effect remains unclear. Curcumin (CUR), an adjuvant drug with anti-inflammatory...

...Cheng Yang; Na Xie; Zhifei Luo; Xiling Ruan; Yixin Zhang; Weijiang Wang; Yousheng Huang Introduction: We investigated the function of cell division cycle 6 (CDC6) on the prognosis in colorectal carcinoma (CRC). Methods: CDC6 protein expression levels in 121 patients with colorectal cancer...

...Jinghu He; Junjie Xing; Xiaohong Yang; Chenxin Zhang; Yixiang Zhang; Hao Wang; Xiaodong Xu; Hantao Wang; Yi Cao; Haonan Xu; Chuansen Zhang; Chen Wang; Enda Yu Objective: Colorectal cancer (CRC) remains a major cause of cancer-related death worldwide. Proteasome 26S subunit ATPase 2 (PSMC2) plays...

...Maria Baimas-George; Erin Baker; Michal Kamionek; J. Stuart Salmon; Amit Sastry; David Levi; Dionisios Vrochides Advances in the systemic treatment of stage IV colorectal cancer with liver metastases has offered improved survival rates for patients who otherwise face a dismal prognosis. However...

...Mark Waddle; Myra Irvin; Eva Gupta; Martin Gibbs; Tanya S. Kakar; Nicole A. Gannon; Jennifer R. Arthurs; Deborah L. Fischer; Sikander Ailawadhi Oxaliplatin is one of the most commonly used drugs for patients with colorectal cancer. It has rarely been associated with disseminated intravascular...

... with the occurrence of adverse events following fluoropyrimidine-based therapies. We describe a case of toxicity grade 5 after the administration of capecitabine and oxaliplatin in a patient with stage III colorectal cancer and DPD congenital deficiency, which was identified later. Several polymorphisms have been...

...Yasumasa Takii; Toshiyuki Yamazaki; Takayuki Okada; Tatsuo Tani; Kazuhiro Funakoshi; Satoshi Maruyama; Jun Hasegawa; Kouhei Akazawa; Katsuyoshi Hatakeyama; for the Niigata Colorectal cancer Chemotherapy Study Group (NCCSG) Background: This study attempted to determine the therapeutic dosage...

...J.K. Fauser; G.M. Matthews; A.G. Cummins; G.S. Howarth Background: Fatty acids are classified as short-chain (SCFA), medium-chain (MCFA) or long-chain and hold promise as adjunctive chemotherapeutic agents for the treatment of colorectal cancer. The antineoplastic potential of MCFA remains...

... or nonhematological toxicity persisting for more than 3 weeks or patient refusal. Hepatic arterial infusion Irinotecan Liver metastases Colorectal cancer Phase I study Despite the existence of excellent screening and preventive strategies, colorectal carcinoma (CRC) remains a major public health...

... antagonizes 5-hydroxytryptamine type 4 receptors. We designed a pilot study in order to explore the optimal dosing period for indisetron during modified FOLFOX6 (mFOLFOX6). Patients and Methods: Forty-two chemotherapy-naive patients with advanced colorectal cancer scheduled to receive mFOLFOX6 were randomly...

...Qian Deng; Chun-mei Huang; Ni Chen; Li Li; Xiao-dong Wang; Wen Zhang; Feng Bi; Qiu-lin Tang; Zhi-ping Li; Wei Wang Bcl-2/E1B 19-kDa interacting protein 3 (BNIP3) is a proapoptotic protein whose expression level is often low in colorectal cancer (CRC) cells due to the BNIP3 gene promoter DNA...

... to be underdiagnosed [ 1 ]. Steatohepatitis Cirrhosis Hepatic steatosis Colorectal cancer Liver metastases © 2012 S. Karger AG, Basel 2012 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized...

... of our study was to investigate the expression of MAC30 mRNA and its correlation with clinicopathological variables in human colorectal cancer (CRC). Methods: MAC30 mRNA expression was first examined in 55 CRCs, along with the samples from the matched distant normal and adjacent noncancerous tissue by RT...

... metastatic colorectal cancer patients. Methods: A total of 39 patients resistant to both oxaliplatin and irinotecan were included in this retrospective study. Treatment consisted of irinotecan 180/m 2 every 14 days, weekly cetuximab standard dose and bevacizumab 5 mg/kg every 14 days. Results: Partial...

... Yubero; Luis Cirera Background: We gathered data from multiple institutions on the cetuximab regimen of patients with metastatic colorectal cancer. Methods: 126 patients from 19 centers were included from July 2006 to July 2007 in this prospective non-controlled study. Irinotecan-refractory metastatic...

... to 5-fluorouracil (5-FU). Method: We investigated correlations of clinicopathological factors with protein expression levels of TS, DPD, OPRT in colorectal cancer (CRC). The subjects were 202 patients who had undergone CRC resection. Result: There was a negative correlation between DPD and OPRT protein...

...Å. Wallin; P. Francis; M. Nilbert; J. Svanvik; X.-F. Sun Aim: Colorectal cancer is the third most common form of cancer in the industrial countries. Due to advances regarding the treatments, primarily development of improved surgical methods and the ability to make the earlier diagnosis...

...Emma Widegren; Sofia Önnesjö; Gunnar Arbman; Hany Kayed; Hanswalter Zentgraf; Jörg Kleeff; Hong Zhang; Xiao-Feng Sun Background: FXYD3 is up-/down-regulated in different types of cancers. We examined FXYD3 expression in colorectal cancers and its relationship to biological and clinicopathological...